


## PHARMACEUTICAL 2022



## Emmaus Life Sciences Inc. Rank 262 of 475





## PHARMACEUTICAL 2022



## Emmaus Life Sciences Inc. Rank 262 of 475

The relative strengths and weaknesses of Emmaus Life Sciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emmaus Life Sciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 136% points. The greatest weakness of Emmaus Life Sciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -135%, being 141% points above the market average of -276%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 9,091             |
| Cost of Goods Sold                          | 3,312             |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 37,100            |
| Liabilities, Non-Current                    | 36,434            |
| Other Assets                                | 47,496            |
| Other Compr. Net Income                     | -1,399            |
| Other Expenses                              | 5,903             |
| Other Liabilities                           | 4,650             |
| Other Net Income                            | -9,793            |
| Property and Equipment                      | 147               |
| Research and Development                    | 4,110             |
| Revenues                                    | 20,610            |
| Selling, General and Administrative Expense | 13,438            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 56,734            |
| Liabilities              | 78,184            |
| Expenses                 | 26,763            |
| Stockholders Equity      | -21,450           |
| Net Income               | -15,946           |
| Comprehensive Net Income | -16,646           |
| Economic Capital Ratio   | -135%             |